However, ranolazine anti-AF efficacy in AF may also be due to its reduction of peak INa and especially its atrial-selective inhibition of the rapid delayed rectifier K+ current (IKr) carried by Kv11.1, the cardiac human ether-a-go-go-related gene (hERG) K+ channel. This evidence concerns the gene KCNH2 and atrial fibrillation.